Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications

Seminars in Cancer Biology

Volumn 23, Issue 5, 2013, Pages 337-343

  Corazzari, Marco ^a,b   Fimia, Gian Maria ^b,c   Lovat, Penny ^d   Piacentini, Mauro ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Autophagy, Melanoma; BRAF; Chemoresistance; Tumorigenesis

Indexed keywords

ANTHRACYCLINE; AUTOPHAGY PROTEIN 5; BECLIN 1; GEMCITABINE; HYDROXYCHLOROQUINE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; RAF PROTEIN; RAS PROTEIN; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TERFENADINE; TETRAHYDROCANNABINOL;

APOPTOSIS; AUTOPHAGY; CARCINOGENESIS; CELL DEATH; CUTANEOUS MELANOMA; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SOLID TUMOR;

AUTOPHAGY, MELANOMA; BRAF; CHEMORESISTANCE; TUMORIGENESIS;

ANIMALS; AUTOPHAGY; CARCINOGENESIS; HUMANS; MELANOMA;

EID: 84884812529     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.07.001     Document Type: Review

References (101)

1. Lum J.J., DeBerardinis R.J., Thompson C.B. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005, 6:439-448.
2. Xie Z., Klionsky D.J. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007, 9:1102-1109.
3. Fimia G.M., Kroemer G., Piacentini M. Molecular mechanisms of selective autophagy. Cell Death Differ 2013, 20:1-2.
4. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012, 12:401-410.
5. Checinska A., Soengas M.S. The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy. Pigment Cell Melanoma Res 2011, 24:1116-1132.
6. Armstrong J.L., Corazzari M., Martin S., Pagliarini V., Falasca L., Hill D.S., et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res 2011, 17:2216-2226.
7. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
8. Tsao H., Chin L., Garraway L.A., Fisher D.E. Melanoma: from mutations to medicine. Genes Dev 2012, 26:1131-1155.
9. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma. Lancet 2005, 365:687-701.
10. Dong J., Phelps R.G., Qiao R., Yao S., Benard O., Ronai Z., et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003, 63:3883-3885.
11. Satyamoorthy K., Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther 2002, 1:14-17.
12. Houghton A.N., Polsky D. Focus on melanoma. Cancer Cell 2002, 2:275-278.
13. Elder D.E., Van Belle P., Elenitsas R., Halpern A., Guerry D. Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 1996, 15:336-348.
14. Gruber S.B., Barnhill R.L., Stenn K.S., Roush G.C. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989, 21:773-780.
15. Dhomen N., Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007, 17:31-39.
16. Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004, 41:270-272.
17. Gilchrest B.A., Eller M.S., Geller A.C., Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340:1341-1348.
18. Maldonado J.L., Fridlyand J., Patel H., Jain A.N., Busam K., Kageshita T., et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003, 95:1878-1890.
19. Thomas N.E., Berwick M., Cordeiro-Stone M. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?. J Invest Dermatol 2006, 126:1693-1696.
20. Hsu M.Y., Meier F.E., Nesbit M., Hsu J.Y., Van Belle P., Elder D.E., et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000, 156:1515-1525.
21. Herlyn M., Padarathsingh M., Chin L., Hendrix M., Becker D., Nelson M., et al. New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B study section. Am J Pathol 2002, 161:1949-1957.
22. Grossmann J. Molecular mechanisms of detachment-induced apoptosis-Anoikis. Apoptosis 2002, 7:247-260.
23. Benjamin C.L., Melnikova V.O., Ananthaswamy H.N. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008, 624:265-282.
24. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
25. Tsao H., Goel V., Wu H., Yang G., Haluska F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337-341.
26. Carvajal R.D., Antonescu C.R., Wolchok J.D., Chapman P.B., Roman R.A., Teitcher J., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305:2327-2334.
27. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
28. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
29. Ellerhorst J.A., Greene V.R., Ekmekcioglu S., Warneke C.L., Johnson M.M., Cooke C.P., et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011, 17:229-235.
30. Cantwell-Dorris E.R., O'Leary J.J., Sheils O.M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011, 10:385-394.
31. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
32. Gray-Schopfer V.C., da Rocha Dias S., Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005, 24:165-183.
33. Lee J.H., Choi J.W., Kim Y.S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164:776-784.
34. Edlundh-Rose E., Egyhazi S., Omholt K., Mansson-Brahme E., Platz A., Hansson J., et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006, 16:471-478.
35. Arkenau H.T., Kefford R., Long G.V. Targeting BRAF for patients with melanoma. Br J Cancer 2011, 104:392-398.
36. Shao Y., Aplin A.E. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ 2012, 19:2029-2039.
37. Corazzari M., Lovat P.E., Armstrong J.L., Fimia G.M., Hill D.S., Birch-Machin M., et al. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer 2007, 96:1062-1071.
38. Lovat P.E., Corazzari M., Armstrong J.L., Martin S., Pagliarini V., Hill D., et al. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 2008, 68:5363-5369.
39. Rutkowski D.T., Kaufman R.J. A trip to the ER: coping with stress. Trends Cell Biol 2004, 14:20-28.
40. Szegezdi E., Logue S.E., Gorman A.M., Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006, 7:880-885.
41. Lin J.H., Li H., Yasumura D., Cohen H.R., Zhang C., Panning B., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007, 318:944-949.
42. Hersey P., Zhang X.D. Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res 2008, 21:358-367.
43. Rutkowski D.T., Kaufman R.J. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci 2007, 32:469-476.
44. Jiang C.C., Chen L.H., Gillespie S., Wang Y.F., Kiejda K.A., Zhang X.D., et al. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 2007, 67:9750-9761.
45. Martin S., Hill D.S., Paton J.C., Paton A.W., Birch-Machin M.A., Lovat P.E., et al. Targeting GRP78 to enhance melanoma cell death. Pigment Cell Melanoma Res 2010, 23:675-682.
46. Senft D., Berking C., Graf S.A., Kammerbauer C., Ruzicka T., Besch R. Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS One 2012, 7:e30821.
47. Dong L., Jiang C.C., Thorne R.F., Croft A., Yang F., Liu H., et al. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 2011, 30:3716-3726.
48. Linder S., Shoshan M.C. Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy. Drug Resist Updat 2005, 8:199-204.
49. Verfaillie T., Salazar M., Velasco G., Agostinis P. Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010, 2010:930509.
50. Carracedo A., Lorente M., Egia A., Blazquez C., Garcia S., Giroux V., et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006, 9:301-312.
51. Hetz C., Thielen P., Matus S., Nassif M., Court F., Kiffin R., et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 2009, 23:2294-2306.
52. Zalckvar E., Berissi H., Eisenstein M., Kimchi A. Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL. Autophagy 2009, 5:720-722.
53. Hoyer-Hansen M., Bastholm L., Szyniarowski P., Campanella M., Szabadkai G., Farkas T., et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 2007, 25:193-205.
54. Roy S., Debnath J. Autophagy and tumorigenesis. Semin. Immunopathol 2010, 32:383-396.
55. Tanida I. Autophagy basics. Microbiol. Immunol 2011, 55:1-11.
56. Mijaljica D., Prescott M., Devenish R.J. Microautophagy in mammalian cells: revisiting a 40-year-old conundrum. Autophagy 2011, 7:673-682.
57. Li W., Yang Q., Mao Z. Chaperone-mediated autophagy: machinery, regulation and biological consequences. Cell Mol Life Sci 2011, 68:749-763.
58. Glick D., Barth S., Macleod K.F. Autophagy: cellular and molecular mechanisms. J Pathol 2010, 221:3-12.
59. Chan E.Y., Tooze S.A. Evolution of Atg1 function and regulation. Autophagy 2009, 5:758-765.
60. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820.
61. Liang C., Feng P., Ku B., Dotan I., Canaani D., Oh B.H., et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006, 8:688-699.
62. Takahashi Y., Coppola D., Matsushita N., Cualing H.D., Sun M., Sato Y., et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007, 9:1142-1151.
63. Yue Z., Jin S., Yang C. Levine AJ and Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003, 100:15077-15082.
64. Kagan R., Zeh H.J., Lotze M.T. Tang D. the Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011, 18:571-580.
65. An C.H., Kim M.S., Yoo N.J., Park S.W., Lee S.H. Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers. Pathol Res Pract 2011, 207:433-437.
66. Zhao Z., Ni D., Ghozalli I., Pirooz S.D., Ma B., Liang C. UVRAG: at the crossroad of autophagy and genomic stability. Autophagy 2012, 8:1392-1393.
67. Maiuri M.C., Tasdemir E., Criollo A., Morselli E., Vicencio J.M., Carnuccio R., et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 2009, 16:87-93.
68. Yang S., Wang X., Contino G., Liesa M., Sahin E., Ying H., et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011, 25:717-729.
69. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011, 25:460-470.
70. Kon M., Kiffin R., Koga H., Chapochnick J., Macian F., Varticovski L., et al. Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med 2011, 3:109ra117.
71. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
72. White E., Karp C., Strohecker A.M., Guo Y., Mathew R. Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol 2010, 22:212-217.
73. Ma X.H., Piao S., Wang D., McAfee Q.W., Nathanson K.L., Lum J.J., et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 2011, 17:3478-3489.
74. Yang Y., Lu Y., Wang C., Bai W., Qu J., Chen Y., et al. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012, 3:171-180.
75. Lazova R., Klump V., Pawelek J. Autophagy in cutaneous malignant melanoma. J Cutan Pathol 2010, 37:256-268.
76. Lazova R., Camp R.L., Klump V., Siddiqui S.F., Amaravadi R.K., Pawelek J.M. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res 2012, 18:370-379.
77. Miracco C., Cevenini G., Franchi A., Luzi P., Cosci E., Mourmouras V., et al. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol 2010, 41:503-512.
78. White E., DiPaola R.S. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009, 15:5308-5316.
79. Swampillai A.L., Salomoni P., Short S.C. The role of autophagy in clinical practice. Clin Oncol (R Coll Radiol) 2012, 24:387-395.
80. Xie X., White E.P., Mehnert J.M. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One 2013, 8:e55096.
81. Bristol M.L., Emery S.M., Maycotte P., Thorburn A., Chakradeo S., Gewirtz D.A. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy?. J. Pharmacol Exp Ther 2013, 344:544-552.
82. Wildenberg M.E., Vos A.C., Wolfkamp S.C., Duijvestein M., Verhaar A.P., Te Velde A.A., et al. Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse. Gastroenterology 2012, 142:1493-1503e6.
83. Lee H.K., Mattei L.M., Steinberg B.E., Alberts P., Lee Y.H., Chervonsky A., et al. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity 2010, 32:227-239.
84. Kovacs J.R., Li C., Yang Q., Li G., Garcia I.G., Ju S., et al. Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. Cell Death Differ 2012, 19:144-152.
85. Townsend K.N., Hughson L.R., Schlie K., Poon V.I., Westerback A., Lum J.J. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev 2012, 249:176-194.
86. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64.
87. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
88. Martins I., Michaud M., Sukkurwala A.Q., Adjemian S., Ma Y., Shen S., et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012, 8:413-415.
89. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
90. Kimura T., Takabatake Y., Takahashi A., Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013, 73:3-7.
91. Kroemer G., Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008, 9:1004-1010.
92. Shen H.M., Codogno P. Autophagic cell death: Loch Ness monster or endangered species. Autophagy 2011, 7:457-465.
93. Shen S., Kepp O., Kroemer G. The end of autophagic cell death. Autophagy 2012, 8:1-3.
94. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11:448-457.
95. Shintani T., Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 2004, 306:990-995.
96. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005, 5:726-734.
97. Garcia-Escudero V., Gargini R., Izquierdo M. Glioma regression in vitro and in vivo by a suicide combined treatment. Mol Cancer Res 2008, 6:407-417.
98. Salazar M., Carracedo A., Salanueva I.J., Hernandez-Tiedra S., Egia A., Lorente M., et al. TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action. Autophagy 2009, 5:1048-1049.
99. Tomic T., Botton T., Cerezo M., Robert G., Luciano F., Puissant A., et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011, 2:e199.
100. Nicolau-Galmes F., Asumendi A., Alonso-Tejerina E., Perez-Yarza G., Jangi S.M., Gardeazabal J., et al. Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis 2011, 16:1253-1267.
101. Vara D., Salazar M., Olea-Herrero N., Guzman M., Velasco G., Diaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 2011, 18:1099-1111.